• Calendar

    August 25-26, 2010 – FDA Boot Camp*** (American Conference Institute) – San Francisco, CA

    August 26, 2010 – "The Future of Patenting in Biomedicine" (Technology Transfer Tactics) – 1:00 – 2:30 PM (EDT)

    September 1-2, 2010 – 7th Annual Pharmaceutical Law Summer School (IBC Legal) – London, UK

    September 7-9, 2010 – BioPatent Design (Pharma IQ) – Munich, Germany

    September 8, 2010 – Biotechnology/Chemical/Pharmaceutical (BCP) Customer Partnership Meeting – 10:00 am – 4:15 pm

    September 12-14, 2010 – 2010 Annual Meeting (Intellectual Property Owners Association) – Atlanta, GA

    September 15, 2010 – Prior Art & Obviousness 2010: Current Trends in Sections 102 & 103 (Practising Law Institute) – San Francisco, CA

    September 16, 2010 – Developments in Pharmaceutical and Biotech Patent Law 2010 (Practising Law Institute) – New York, NY (Groupcasts to be held in Philadelphia, PA; Pittsburgh, PA; Mechanicsburg, PA; New Brunswick, NJ; and Boston, MA)

    September 20-21, 2010 – Patent Litigation 2010 (Practising Law Institute) – San Francisco, CA

    September 20-22, 2010 – 2nd Annual Business of Biosimilars (Institute for International Research) – Boston, MA

    September 22-23, 2010 – Biosimilars & Biobetters: Aligning Business & Science for Success*** (SMi Conferences) – London, UK

    September 27-28, 2010 – FDA Boot Camp*** (American Conference Institute) – Boston, MA

    September 30, 2010 – Advanced Patent Licensing 2010: Current Developments and Best Practices (Practising Law Institute) – Chicago, IL

    October 4-5, 2010 – Patent Litigation 2010 (Practising Law Institute) – McLean, VA

    October 6-7, 2010 – Maximizing Pharmaceutical Patent Lifecycles*** (American Conference Institute) – New York, NY

    October 14-15, 2010 – Patent Litigation 2010 (Practising Law Institute) – Chicago, IL

    October 18-19, 2010 – 5th Summit on Biosimilars and Follow-on Biologics*** (Center for Business Intelligence) – Washington, DC

    October 25, 2010 – Advanced Patent Licensing 2010: Current Developments and Best Practices (Practising Law Institute) – San Francisco, CA

    November 8, 2010 – Advanced Patent Licensing 2010: Current Developments and Best Practices (Practising Law Institute) – New York, NY (Groupcasts to be held in Atlanta, Philadelphia, Pittsburgh, and Mechanicsburg, PA)

    November 8-9, 2010 – Patent Litigation 2010 (Practising Law Institute) – Atlanta, GA

    November 15-16, 2010 – Patent Litigation 2010 (Practising Law Institute) – New York, NY (Groupcasts to be held in Philadelphia, Pittsburgh, and Mechanicsburg, PA)

    January 26-27, 2011 – The Life Sciences Lawyer's Guide to Patent Term Adjustment and Patent Term Extensions*** (American Conference Institute) – New York, NY

    ***Patent Docs is a media partner of this conference or CLE

  • USPTO Seal - background The U.S. Patent and Trademark Office has announced the agenda for the next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting to be held on September 8, 2010.  The proposed agenda is as follows:

    Morning Session

    • Greetings and Overview (10:00 – 10:15 am EDT):  Jackie Stone, George Elliott, and Remy Yucel, Directors, Technology Center 1600

    • Patent Reengineering Team (10:15 – 11:45 am):  Christian Chace, SPE, Art Unit 2187 and Marti Hearst, External Affairs

    • Break (11:45 – 12:00 pm)

    • Best Practice for PTE (12:00 pm – 12:45 pm):  Mary Till, Office of Patent Legal Administration

    • Lunch (12:45 – 2:00 pm)

    Afternoon Session

    • Section 101, Utility and Patentable Subject Matter in the Discovery Arts (2:00 – 3:00 pm):  Benjamin Borson, Borson Law Group, LLP

    • Break (3:00 – 3:15 pm)

    • Broadening Reissues (3:15 – 4:00 pm):  Bennett Celsa, QAS, TC1600

    • Closing Remarks/Discussion (4:00 – 4:15 pm):  Jackie Stone, George Elliott, and Remy Yucel, Directors, Technology Center 1600

    The meeting can be attended in person at the USPTO's Madison Auditorium, 600 Dulany Street, Alexandria, VA, or viewed online here (select the "enter as guest" option).  The Patent Office asks that non-USPTO employees login using their e-mail addresses.

  • By Kevin E. Noonan

    USPTO Seal Many of the amicus curiae briefs that have been filed in the en banc rehearing of Therasense, Inc. v. Becton, Dickinson & Co. have mentioned (if not bemoaned) the negative effects the Federal Circuit's inequitable conduct jurisprudence has had on the functioning of the U.S. Patent and Trademark Office.  So the content of the PTO's own brief, filed in support of neither party, is of great interest.  As might be expected, the Office also believes that how the Federal Circuit has developed the case law on inequitable conduct has increased the burdens on the Office and led to inefficiencies that have contributed to the current backlog of unexamined applications.  Unlike some of the other amici, however, the Office's brief takes a more Goldilocks approach to the question of how to remedy the situation, disagreeing with those who take the position that dramatic changes must be effected by the en banc Court.

    Like other briefs, the PTO's brief argues that a large portion of the problems it faces stem from the "multiple formulations" for both the materiality and intent prongs that have arisen as the inequitable conduct case law was developed since the last time the Court considered the issue en banc (Kingsdown Medical Consultants, Ltd. v. Hollister Inc.).  As a consequence, and coupled with the sanction of unenforceability, the brief argues that patent applicants "with some regularity . . . [either] minimize their exposure to material information," for example by foregoing prior art searches, or "submit to the agency large numbers of prior art references of questionable materiality."  Neither alternative fosters the Office's mission, says the brief, and the situation has made the Office "deeply concerned."

    The brief starts its legal (as opposed to policy) arguments by tracing the origins of the inequitable conduct doctrine to both common law fraud and the equitable principle of unclean hands.  The brief cautions against "adjusting" the standards for inequitable conduct in favor of either one over the other, asserting that the doctrine could become "murkier" (if predicated too heavily on unclean hands) or too rigid (if predicated too heavily on common law fraud principles).  The Office finds the Golden Mean between these two doctrines in its own Rule 56, which should be the standard of materiality applied by the courts.  One benefit of using Rule 56, according to the brief, is that the Office "is in the best position to know what information is essential to determining the patentability of a claimed invention," reflecting the Office's "expertise and experience."  The brief also says Rule 56 is "consistent with Supreme Court precedent and provides clear guidance to applicants" concerning the information that should be submitted to comply with the duty of disclosure.

    In support of its argument on this materiality standard, the brief parses the now-familiar trilogy of Supreme Court cases that represent the genesis of the inequitable conduct doctrine:  Keystone Driller Co. v. General Excavator Co., 290 U.S. 240 (1933); Hazel-Atlas Glass Co. v. Hartford-Empire Co., 322 U.S. 238, 250-51 (1944); and Precision Instrument Mfg. Co. v. Automotive Maintenance Machinery Co., 324 U.S. 806, 814 (1945).  The brief also notes the role of the CCPA in crafting the modern inequitable conduct doctrine in Norton v. Curtiss, 433 F.2d 779 (CCPA 1970), saying that the Federal Circuit's predecessor court "blended" the earlier doctrines, "borrowing the materiality and intent elements from common law fraud; but expanding the type of conduct swept into each to account for the unclean hands doctrine."  The basis for the court's blending was, the brief asserts, to "make an applicant's duty of honesty and candor to the PTO meaningful."  In this milieu, honesty and candor, the court opines, are "necessary," even "essential" elements.  And in the Office's opinion, the CCPA achieved an "appropriate" blend, leading to a "sound" inequitable conduct basis.

    In addition to being a product of the Office's own expertise, the Office argues that Rule 56 should be the standard of materiality applied by the courts in the face of the extant "five different standards for materiality" (objective "but for"; subjective "but for"; the "but it may have been" standard; the "reasonable examiner" standard; and, of course, Rule 56).

    The brief argues that the Rule 56 standard is objective (as opposed to the reasonable examiner standard), and that it utilizes the Office's own competency in deciding what art is material to patentability.  In addition, the brief argues that Rule 56 "presents clear and straightforward guidance for applicants regarding what information they should submit to the PTO to satisfy [the] duty of disclosure."  The Office also distinguishes Rule 56 from the "but for" standards argued by other amici, on the grounds that the latter standard would permit applicants "to engage in a level of purposeful gamesmanship" regarding patentability.  In contrast, the Office argues, using Rule 56 "ensures that applicants deal honestly with the agency about all patentability matters."  Such a standard of honesty is consistent with the Supreme Court's recognition of the public interest aspects of patents.  Finally, with regard to materiality, the brief disavows the former "reasonable examiner" standard, which was too vague, ambiguous and difficult to consistently apply.

    The brief further distinguishes its Rule 56 recommendation from the "but for" standard espoused by others by stating that the "but for" standard is too narrow, inter alia by requiring the accused infringer to prove invalidity before inequitable conduct, "leaving little work for the inequitable conduct doctrine to do."  The brief also cautions that using a "but for" standard would permit applicants to freely "engage in a wide variety of misconduct," provided that "it could not later be proven that the patent would not have issued "but for" the misconduct.  In addition, according to the brief, the "but for" standard is contrary to Supreme Court precedent, and it contends that a case used elsewhere to support the "but for" standard, Corona Cord Tire Co. v. Dovan Chemical Corp., did not fail to find inequitable conduct so much as fail to consider a defense that had not been asserted.

    The brief also rejects the notion that inequitable conduct could be relegated to an administrative disciplinary proceeding.  The procedural circumstances are ill-fitted to the Office moving that quickly to bring a complaint.  Moreover, the Office does not have the resources to perform the kinds of investigations necessary for the Office's disciplinary actions to be much of an administrative remedy for a torrent of inequitable conduct cases.

    Turning to the intent prong, the PTO's brief urges that deceptive intent be "judged by the single most reasonable inference" standard in view of the totality of the evidence.  Specific intent, the brief argues, is consistent not only with Supreme Court precedent but also the Federal Circuit's own earlier precedent in Kingsdown Medical.  While not foreclosing evidence of materiality to be used as one of the "circumstances" to be considered, the brief emphasizes that the intent prong must be separately proven by clear and convincing evidence.

    The brief recognizes two conflicting (or at least not consistent) lines of precedent regarding the intent to deceive:  the first, exemplified by Ferring B.V. v. Barr Labs., Inc., regarding the "knew or should have known" standard, and Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., where the standard is closer to a inference being drawn than based on the evidence, but one representing "the single most reasonable inference to be drawn regarding intent."  The brief argues that the test in Ferring steps into some important priority questions with regard to the standard for intent.  The brief argues that the Ferring Court was over-inclusive by adding gross negligence to the intent prong of the test, something prohibited by both the Supreme Court (in Ernst & Ernst v. Hochfelder, 425 U.S. 185 (1976); securities fraud liability) and the Federal Circuit (Kingsdown Medical).  This inclusion is not warranted, as in any of the trilogy of cases discussed herein, which involved "affirmative deception and not negligence."  The brief also notes that in rejecting negligence as satisfying the intent prong, the Court should also reject the "should have known" standard.  In view of the severity of the sanction, the PTO argues that the "underlying mental state of the intent prong should be correspondingly high."  Citing Star Scientific, the brief argues that it is just as inequitable to "strike down an entire patent where the patentee only committed minor missteps or acted with minimal culpability" as it is to enforce a patent obtained through inequitable conduct.  The brief returns to its policy concerns by noting that "raising" the intent standard to require specific intent would reduce the incentive on applicants to (over) submit "an excessive number of prior art references that may or may not be material."

    The Office's brief also breaks ranks with other amici over the question of equitable balancing of evidence in the materiality and intent prongs, trusting that it would be the "rare case" where a court would find materiality and intent both by clear and convincing evidence and then not hold that inequitable conduct had been proven.  The brief argues that, while both intent and materiality must be established independently, materiality can be used as evidence for intent.  The lynchpin of this argument is that the applicant must be shown to have been aware ("appreciated the materiality of the [withheld] information"), and that this is not applied according to a "sliding scale."  Indeed, the brief argues that the Court should consider the degree to which the "sliding scale" is "misunderstood" and that the Court should "clarify that a high degree of materiality does not mean that only a negligible amount of intent is desired."  But the brief accepts that the absence of a credible explanation of the failure to disclose material information can be considered when inferring intent.

    Conversely, the brief argues that the way the Court balances intent and materiality should be "clarified."  The reasonable expectation is that a finding of both materiality and intent generally will lead to a finding of inequitable conduct.  But this cannot devolve into formula, according to the brief, in view of the equitable roots of the doctrine and Supreme Court precedent.  "Balancing" is not accurately represented as a sliding scale or a rigid rule.  "Rather, it simply requires a court to consider all of the evidence of record" in rendering a decision.

    Finally, the brief argues that standards of materiality and intent from other agencies are not helpful in properly interpreting these factors with regard to inequitable conduct.

    For additional information regarding this topic, please see:

    • "American Bar Association Files Amicus Brief in Therasense Case," August 17, 2010
    • "Therasense, Inc. v. Becton, Dickinson & Co. — Briefing Schedule Update," August 8, 2010
    • "BIO Files Amicus Brief in Therasense Case," August 8, 2010
    • "Pharma and Software Companies File Joint Amicus Brief in Therasense Case," August 3, 2010
    • "IPO Files Amicus Brief in Therasense Case," August 2, 2010
    • "Abbott Files Brief in Therasense Case," July 28, 2010
    • "CAFC Sets Date for Oral Argument En Banc in Inequitable Conduct Appeal," June 9, 2010
    • "Therasense, Inc. v. Becton, Dickinson & Co. — Briefing Schedule Update," May 16, 2010
    • "Therasense, Inc. v. Becton, Dickinson & Co. Briefing," May 13, 2010
    • "Federal Circuit Grants En Banc Review in Therasense v. Becton Dickinson," April 28, 2010

  • By James DeGiulio —

    Lilly's Patent for Strattera Found Invalid, Lilly Appeals to Federal Circuit

    Lilly Teva Pharmaceuticals USA, Mylan Pharmaceuticals, and Apotex successfully argued that Eli Lilly's patent for the ADHD drug Strattera (U.S. Patent No. 5,658,590) lacked utility, thus invalidating the '590 patent and opening the door for generic versions of the drug.  Responding immediately, Lilly appealed the decision to the Federal Circuit and moved for a temporary injunction to prevent generic market entry until the decision on appeal.

    On August 9, 2007, Lilly brought suit against Actavis in the U.S. District Court for the District of New Jersey for infringement of the '590 patent (see "Court Report," August 19, 2007).  One month later, Lilly amended its complaint, including Glenmark, Sun, Sandoz, Mylan, Teva, Apotex, Aurobindo, Synthon, and Zydus as defendants.  In the months that followed, Lilly settled with Zydus, Glenmark, Synthon, Teva, and Actavis.  On December 29, 2009, Judge Dennis Cavanaugh determined the remaining defendants had induced infringement of the '590 patent by filing ANDAs for generic versions of Strattera.  The judge declined to grant summary judgment motions to either side at that time, saving questions on the patent's validity for trial.

    On August 12, Judge Cavanaugh found that Lilly's 1995 application for the '590 patent had not included test results required to prove the drug's utility.  Although Lilly completed clinical trials on the product after submitting its application, the invalidity inquiry demands that the Court consider utility at the time of filing.  Judge Cavanaugh noted that at the time of filing, a person of skill in the art would not have recognized the drug's efficacy without the test results.  The judge rejected the defendants' obviousness and inequitable conduct arguments, but invalidated the '590 patent for lack of utility.  The '590 patent had been set to expire in November 2016.

    Acting quickly, Lilly filed a motion on August 16 seeking a temporary injunction barring the seven remaining defendants in the infringement suit from launching generic versions of Strattera while the Federal Circuit decides Lilly's appeal of the invalidity ruling.

    Judge Cavanaugh's invalidity order can be found here, and Lilly's motion for temporary injunction can be found here.


    Daiichi, Apotex Reach Settlement In Evoxac Patent Suit

    Daiichi Sankyo Daiichi Sankyo has reached a settlement and licensing agreement with Apotex in its patent infringement suit over Daiichi's dry mouth drug Evoxac, thus paving the way for Apotex to market a generic version of the drug in 2012.

    Apotex #1 The suit originated in June 2009 when Daiichi sued Apotex in the U.S. District Court for the District of Delaware in response to an ANDA covering a generic version of Evoxac (see "Court Report," July 5, 2009).  In response, Apotex argued that its product would not infringe Daiichi's U.S. Patent No. 5,340,821 and that the patent was invalid.  The parties filed a stipulation of dismissal in March 2010, and Judge Jerome Simandle dismissed the case without prejudice three days later.

    According to a Daiichi spokesperson, the August 5 agreement resolves the parties' dispute and the settlement ends the case.  Under the agreement, Apotex's license will allow it to launch its generic cevimeline hydrochloride product in late 2012.


    Arbitration Award to Roche and Gen-Probe Approved in HPV License Suit with Qiagen

    Roche The 2009 arbitration proceeding that granted significant attorneys' fees to Roche and Gen-Probe was affirmed in federal court, thus confirming that Roche did not violate a cross-licensing agreement with Qiagen over the development of an exclusive test for diagnosing human papillomavirus.

    QIAGEN In December 2006, Qiagen (then Digene) alleged before the International Centre for Dispute Resolution (ICDR) that Roche had breached its cross-licensing agreement when it entered into a supply deal with Gen-Probe for designing sequences for HPV detection kits.  Qiagen argued that only end-user products could be provided, not the oligo probe products.  Gen-Probe intervened in the dispute, and the ICDR concluded in March 2009 that Roche was allowed to provide Gen-Probe with the oligo probes under the licensing agreement.  The panel awarded attorneys' fees of $3.2 million for Roche and $3 million for Gen-Probe.  In August 2009, Qiagen filed a petition in New York state court seeking to vacate or modify the final award, while Roche and Gen-Probe filed petitions in the U.S. District Court for the Southern District of New York to get the award confirmed.  The cases were subsequently consolidated in the Southern District.

    On August 11, Judge Pauley affirmed the 2009 arbitration award in favor of Roche and Gen-Probe in its entirety, including awards of attorneys' fees.  Judge Pauley approved Gen-Probe's intervention and rejected Qiagen's assertions that the panel exceeded its powers by awarding Roche and Gen-Probe attorneys' fees.  The judge simultaneously denied a motion to vacate by Qiagen, which had accused Roche of breaching the licensing agreement when it entered into the supply deal with Gen-Probe.

    Judge Pauley's order can be found here.

  • By Donald Zuhn

    IPO #2 In June, the U.S. Patent and Trademark Office published a notice in the Federal Register (75 Fed. Reg. 33584) seeking comments regarding a number of changes to current restriction practice that the Office is considering implementing (see "USPTO Requests Comments Regarding Proposed Changes to Restriction Practice").  Last week, the Intellectual Property Owners Association (IPO) responded to the Office's call for comments with a letter from IPO President Douglas Norman outlining the organization's position on the issue.

    Rather than specifically responding to the half dozen questions posed in the USPTO notice, the IPO notes that it "has consistently supported the introduction of the Unity of Invention Standard into USPTO practices" (citing a letter the IPO sent to then Director James Rogan more than seven years ago), and then recommends that the Office "consider a broad change to Unity of Invention practice similar to that utilized in the Patent Cooperation Treaty (PCT)."

    The Unity of Invention standard is set out in PCT Rule 13.  In particular, Rule 13.1 requires that an international application "relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ('requirement of unity of invention')," and Rule 13.2 states that:

    [T]he requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.  The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

    The IPO letter provides five reasons for changing to a Unity of Invention standard:  improved efficiency through the use of a single standard, reduced application filings, benefits to applicants and third parties, enhanced opportunities for work sharing, and further harmonization of U.S. patent practice.  Noting that U.S. examiners already use the Unity of Invention standard when examining national stage applications, the IPO observes that "U.S. examiners should already be familiar with Unity of Invention practice."  The letter asserts that "[s]hifting continuously from Restriction Practice on certain cases to the Unity of Invention Standard on others is an unnecessary complication for examiners," and that such shifting "can lead to a blurring of the distinction between the two standards and application of the incorrect standard."

    The IPO also contends that by applying a Unity of Invention standard, the Office could decrease the application backlog by reducing divisional filings, which the IPO suggests are essentially "rework" applications on par with Requests for Continued Examination.  The letter states that "[b]y rolling together related applications falling within a single inventive concept, the total number of examiner hours spent per inventive concept would be reduced."  The letter also states that under current restriction practice, "rejections based upon 'improper Markush Groups' lead to splintering the invention into many separate applications" which is burdensome to both applicants and the Office.  The IPO contends that the Unity of Invention standard would solve this problem by "simplifying prosecution for applicants seeking claims with Markush groups and/or nucleic acid or amino acid sequences."

    According to the letter, application of a Unity of Invention standard would also benefit applicants and third parties.  In particular, the IPO believes that applicants would benefit because they could more readily keep claims relating to the same commercial embodiment in one application, and third parties would benefit because it would be "easier to address method and device claims relating to a single product in a single patent."

    In addition to permitting U.S. examiners to apply only one standard, moving to a Unity of Invention standard would avoid duplication of work and reduce application backlogs worldwide.  The letter notes that in the USPTO's Patent Prosecution Highway (PPH) programs, for example, "studies show that most of the rejections issued by U.S. examiners after receiving allowed claims from foreign patent offices relate to the U.S. application of the Restriction Practice."

    Finally, the IPO declares that "[f]or the USPTO to adopt a common Unity of Invention standard similar to that utilized by virtually all of the other patent offices worldwide would be a bold step in jumpstarting harmonization."

    In addition to the above rationales, the letter provides a few considerations regarding a possible move to a Unity of Invention standard.  With regard to statutory implications, the letter contends that "the USPTO could change to a Unity of Invention standard along the lines of the PCT without any statutory modification needed," because 35 U.S.C. § 121 provides no guidance as to what constitutes "independent and distinct inventions," which may be restricted under the statute.  In addition, the IPO notes that "[t]he issuance of U.S. patents from National Phase applications to which Unity of Invention is already applied illustrates that the Unity of Invention standard can fit within the current statutory framework."  The letter acknowledges that some accommodation may be needed from the Treaty, as "divisional applications are not permitted under the PCT and, accordingly, when a separate invention is identified under the PCT Unity of Invention standard, the applicant is given a choice to maintain those claims in a single application and pay for a separate search or limit the application to only search one of these inventions."  The letter notes, however, that the EPO, JPO, and KIPO all apply the Unity of Invention standard and permit divisional filings

  • By Tim Peterson —

    Judge Rader The Federal Circuit will soon be addressing the issue of patentable subject matter as it relates to biotechnology patents in a trilogy of cases:  Prometheus Laboratories, Inc. v. Mayo Collaborative Services, Classen Immunotherapies, Inc. v. Biogen Idec, and Association for Molecular Pathology v. U.S. Patent and Trademark Office ("Myriad").  In the Myriad case, Plaintiffs/Appellees recently moved for recusal of Chief Judge Randall R. Rader (at right) before the panel has even been chosen (see "Appellees Move for Recusal of Chief Judge Rader in AMP v. USPTO Appeal").  Given the controversy that has ensued, this article first asks whether the Chief Judge would have any influence over these three cases in the event that he is not chosen for a panel, and then analyzes some of Chief Judge Rader's views on patentable subject matter from comments he made before the Supreme Court decided Bilski v. Kappos.  Of particular interest are the similarities and differences between the analysis in Chief Judge Rader's In re Bilski dissent and that of the Supreme Court's majority decision in Bilski v. Kappos.  A second article will delve deeper into the Chief Judge's comments on patentable subject matter.

    Chief Judge Rader's (Lack of) Added Direct Influence As Chief Judge

    Chief Judge Rader is a highly respected member of the Federal Circuit, but his recent promotion to chief judge gives no insight into any influence he has on the Court.  The succession of chief judge is solely determined by 28 U.S.C. § 45:  "The chief judge of the circuit shall be the circuit judge in regular active service who is senior in commission of those judges who – (A) are sixty-four years of age or under; (B) have served for one year or more as a circuit judge; and (C) have not served previously as chief judge."  A qualified judge, however, may chose not to be chief judge, and the chief judge can resign his role at any time.  Judges who have taken senior status are not in "active service" and are ineligible.  Judges Newman and Lourie are both active judges who each have more seniority than the Chief Judge ("senior in commission"), but both are ineligible because of their ages.  So, Judge Rader is chief judge simply because he is the longest serving, non-senior judge (status or citizen).

    Any additional influence the chief judge has over case law as a result of his title is minor.  The chief judge's additional role is primarily administrative.  Chief Judge Rader spoke about his role in determining case law as follows:

    In terms of the substance of the Court, the Chief Judge doesn't have a largely different role than any other Judge.  He can request an en banc poll just as any other Judge.  He perhaps receives a little more attention from his colleagues because his colleagues know that he is often asked to speak for the Court and makes an effort to properly reflect the Court's viewpoints on things.  But in terms of the substance of the Court's law, the Chief Judge acts as one of the other Judges.  He is first among many and I don't think he has a largely different responsibility in terms of defining the Court's law.

    Gene Quinn, An on the Record Interview with CAFC Judge Randall Rader, IPWatchdog, ¶ 13 (April 12, 2010.

    The chief judge normally "preside[s] at any session of court which he attends."  28 U.S.C. § 45.  But other active judges "preside according to the seniority of their commissions," id. So, Chief Judge Rader only presides out-of-turn before Judges Newman and Lourie.

    Similarly, when cases are decided, Chief Judge Rader has a role comparable to another senior-in-commission judge.  The Chief Judge spoke of the process as follows:

    When we come off of the bench we immediately sit down as a panel of 3 and convene our conference.  The junior most Judge always speaks first, and we do that for two reasons.  One is to ensure a kind of judicial independence.  The junior Judge cannot defer to the more experienced senior Judges, but must prepare his or her own independent opinion, which will be presented first in an oral fashion.  And there is another reason for it, and that is if the first Judge and the second Judge differ then the presiding Judge can kind of rock back in his or her chair and listen, let the two Judges represent the case and receive the benefits of that revisitation of the issues before making a decision that will decide the outcome of the case.

    Quinn, supra.

    Federal Circuit Seal The Chief Judge also has little additional influence into deciding panels for cases.  According to the Federal Circuit's Internal Operating Procedures, "[t]he chief judge provides to the clerk's office a list of judges that are available for an argument session.  The clerk's office runs a computer program that randomly generates three-judge panels for each month, subject to the judges' availability."  Internal Operating Procedures ("IOP") #3, downloaded August 5, 2010.

    Related to Prometheus and Classen, "[a] remand from the Supreme Court is referred to the panel or to the en banc court that decided the matter.  . . .  (or if the original panel cannot be reconstituted, the remaining judges of that panel and one or two newly selected judges)." Id., IOP #15.  For Prometheus, Judge Lourie will be on the panel on remand (Chief Judge Michel and District Judge Ron Clark, sitting by designation, were also on the original panel); and for Classen, Judge Moore and Judge Newman will be on the panel (District Judge Joseph Farnan, sitting by designation, was also on the original panel).  The remaining judges on those panels will be chosen randomly.

    Similarities in Analysis Between Chief Judge Rader's Dissent and the Supreme Court Majority

    If Chief Judge Rader does not have additional influence over Prometheus, Claussen, and Myriad because of his role as chief judge, might he have influence because of his ideas about patentable subject matter?  The Chief Judge, in his In re Bilski dissent, was the only judge on the Federal Circuit to hold that Bilski's claims were unpatentable because they were directed toward an abstract idea.  The same was held by Justice Kennedy's majority opinion of Bilski v. Kappos.  Chief Judge Rader went on to ask other questions and draw other conclusions that the Supreme Court majority did not reiterate, which may or may not be predictive of future cases.

    Supreme Court Seal The Chief Judge's dissent was similar to Justice Kennedy's majority opinion in that both found that Bilski's claims were directed toward an abstract idea and followed a very similar path to reach that conclusion.  Justice Kennedy's majority opinion separated the arguments against patentability into three categories:  "(1) it is not tied to a machine and does not transform an article; (2) it involves a method of conducting business; and (3) it is merely an abstract idea."  Of the Federal Circuit's In re Bilski opinions, the majority created the Machine-or-Transformation test as the "sole test" for patentable subject matter (1).  Judge Dyk's concurrence also argued that business method patents should be categorically excluded from patentable subject matter (1 & 2).  Judge Mayer dissented, arguing that Bilski's claims were not patentable solely because business method claims are not patentable subject matter (2).  Judge Newman argued none-of-the-above — that Bilski's claims were directed toward patentable subject matter but should likely be rejected on other grounds (§ 102 lack of novelty, § 103 obviousness, or § 112 written description/enablement).  Only Chief Judge Rader argued that the claim lacked patentable subject matter because it is "merely an abstract idea," which is what the Supreme Court ultimately held.

    In arriving at the same conclusion, Chief Judge Rader and Justice Kennedy followed similar paths.  Both argued that patentable subject matter of § 101 is broad, emphasizing the word "any" in the statute.  Both cited Diehr for the idea that (1) the language of § 101 should be interpreted by its "common, ordinary and contemporary meaning," and (2) "courts 'should not read into the patent laws limitations and conditions which the legislature has not expressed.'"  Both also quoted Thomas Jefferson, that "ingenuity should receive liberal encouragement" as the purpose of patent law.  Both concluded that patentable subject matter should only be limited by three exceptions, "abstract ideas, laws of nature and natural phenomena."  Finally, both held that Bilski's claims were unpatentable subject matter because they were directed toward an abstract idea.

    Differences Between Chief Judge Rader's Dissent and the Supreme Court Majority

    Of course, the devil is in the details, and Justice Kennedy and Chief Judge Rader didn't necessarily agree on the definition of "abstract idea."  Justice Kennedy's opinion, as clarified by Justice Breyer's concurrence, held that "machine-or-transformation" was still an important test, and that the "useful, concrete and tangible result" test of State Street remained overturned.  Justice Kennedy also held, "[t]he Court, therefore, need not define further what constitutes a patentable 'process,' beyond pointing to the definition of that term provided in §100(b) and looking to the guideposts in Benson, Flook and Diehr."  Chief Judge Rader had a more narrow view of what is not patentable subject matter.  First he differentiates between "abstract ideas" and "laws of nature and natural phenomena."  Then he limits abstract claims to those so abstract that they could not be examined.  The Chief Judge is likely to revise some of these views in light of Bilski v. Kappos.  It remains to be seen whether his other ideas will have influence over the Federal Circuit in the upcoming cases.

    Part II of this series will take a deeper look at the Chief Judge's comments on patentable subject matter.

    Tim Peterson most recently worked in the pharmaceutical industry for Merck as a biologist and has a Masters degree in bacteriology from the University of Wisconsin at Madison.  Mr. Peterson is a third-year law student at the Chicago-Kent, School of Law and was a member of MBHB's 2010 class of summer associates.  He can be contacted at timfpeterson@yahoo.com.

  • By Alejandro Luna —

    Mexican Patent Office - Instituto Mexicano de la Propiedad Industrial On Friday, August 13, 2010, the Mexican Trademark and Patent Office (IMPI) made available through its website the new edition of the Linkage Gazette (Mexican health and IP law regulations require IMPI to publish a gazette every six months listing patents in force that cover allopathic drugs).  Regrettably, IMPI decided to exclude formulation patents, limiting the inclusion criteria to compound patents.  There are formulation patents included in the list derived from individual Court orders in litigation proceedings where the non-inclusion of specific formulation patents in the Gazette was contested.

    The current non-inclusion of formulation patents disregards a petition by the Pharmaceutical Association of R&D companies (AMIIF), and does not follow the jurisprudence of the Mexican Supreme Court ruling that formulation patents are to be included in the Linkage Gazette (see "Mexican Supreme Court Decides on Broad Interpretation of Linkage Regulations").

    Mexico Seal Legally, as an administrative authority, IMPI is not bound to follow judicial precedents; nevertheless, there is broad dissatisfaction with the political decision taken by IMPI regarding the denial to include formulation patents in the Linkage Gazette, since following the Supreme Court's criterion would have avoided further litigation from patent holders.

    The non-inclusion of valuable formulation patents can be contested within the next fifteen working days.  Any litigation proceeding at this point will benefit from Supreme Court precedent, which is mandatory for District and Circuit Courts and provides guidelines to decide these cases.

    Of course, inclusion of formulation patents in the Linkage Gazette provides grounds to prevent or challenge marketing authorizations granted to third parties in violation of formulation patents which in many cases have expiration dates beyond the initial compound patent.

    Additionally, inclusion of formulation patents is pivotal, as the formulation of drugs is reviewed by the Regulatory Authority (COFEPRIS) upon studying applications for marketing authorizations.  Since safety and efficacy of a drug reviewed by COFEPRIS is not limited to compounds, there is no rationale to limit the linkage regulation to compound patents by the linked authorities (IMPI and COFEPRIS), particularly when the highest Court in México has decided that formulation patents for allopathic medicines including an identified compound should be included in the Gazette.

    A copy of the Gazette can be found here.

    Alejandro Luna is a partner at Olivares & Cia in Mexico.  He can be contacted at alf@olivares.com.mx.

  • By Kevin E. Noonan

    ABA The American Bar Association (ABA) has filed a brief in the Therasense, Inc. v. Becton, Dickinson & Co. case, in support of neither party but arguing forcefully that the current state of the Federal Circuit's jurisprudence on inequitable conduct is in need of correction.  The brief follows a recommendation from the Intellectual Property Law (IPL) committee of the Association, identified as ABA Report with Recommendation #107B (Policy adopted August 2009), included with the brief as an appendix.  This recommendation stemmed from the work of a Task Force established by the ABA-IPL with instructions to "start from scratch" and "develop a comprehensive, consensus policy on the [inequitable conduct] defense for use in both legislative and judicial advocacy."  The brief states that the Report was the result of meetings with "diverse members of the legal profession and various ABA entities," including the Section of Administrative Law and Regulatory Practice, the Section on Science and Technology, the Business Law Section, and the Section on Litigation.

    The ABA advocates the following requirements for establishing an inequitable conduct defense:

    [I]nequitable conduct [is] shown only upon proof by clear and convincing evidence that: (1) a person having a duty of candor and good faith to the PTO misrepresented or omitted material information; (2) in the absence of such misrepresentation or omission, the PTO, acting reasonably, would not have granted or maintained in force at least one patent claim; and (3) the misrepresentation or omission was made with a specific intent to deceive the PTO, which intent cannot be established by the mere materiality of the misrepresentation or omission.

    The brief also sets forth the reasons the ABA believes changing the current inequitable conduct standard is necessary.  These include themes common in Appellants' brief and several other amicus briefs (and indeed, frequently voiced by commentators and even Chief Judge Rader himself), that the defense is plead too often, with too little basis, and with deleterious effects on both patent litigation and prosecution before the PTO.  This belief is supported by statistics showing that the frequency of inequitable conduct appeals doubled between 2004-2008 (Rader, 2010, Always at the Margin: Inequitable Conduct in Flux, 59 Am. U. K. Rev. 777,779), but that inequitable conduct was found only 25% of the time (citing statistics from the University of Houston Law Center at http://patstats.org).  For example, in 2009, defendants established the defense only 6 out of 38 times it was plead (~15% success rate).

    The brief asserts that the ABA has concluded, "after careful study," that this "excessive invocation of the inequitable conduct defense" is the result of the "vagueness" of the Court's current test for establishing inequitable conduct.  This "vagueness" includes the multiplicity of standards (5) that the Court has sanctioned, including the current PTO standard, the earlier PTO "reasonable examiner" standard, and the "objective but for," subjective "but for," and "but it may have" standards, citing Digital Control Inc. v. Charles Machine Works, 437 F.3d 1309,1314-1316 (Fed. Cir. 2006).  In addition to these different tests, with different levels of materiality and proofs of materiality, the Court has also permitted a showing of materiality to reduce the required evidence of intent (citing American Hoist & Derrick Co. v. Sowa & Sons, Inc., 725 F.2d 1350 (Fed. Cir. 1984).  The brief particularly highlights the inherent subjectivity and imprecision of the "reasonable examiner" test, stating that "the fact that this standard is still applied after-the-fact in litigation leads to the untenable situation where a patentee may be found to have committed inequitable conduct even though he or she fully complied with the applicable PTO regulations."  Moreover, using this standard makes possible situations where "the entire patent (and possibly related patents) may be rendered unenforceable based upon the misrepresentation or omission of anything later deemed to have been 'important' even where every requirement for patentability has been met, and there is no injury to the public through the issuance of otherwise invalid claims."

    The brief also asserts the Report's conclusion that the application of the inequitable conduct defense by the Court has "permitted inequitable conduct to found based on the mere fact that misrepresented or omitted information is material — in the absence of any other evidence of deceptive intent," citing the Court's opinions in Praxair, Inc. v. ATMI, Inc., 543 F.3d 1306, 1313-14 (Fed. Cir. 2008), Ferring B.V. v. Barr Labs., Inc., 437 F.3d 1181, 1191 (Fed. Cir. 2006), and Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059, 1070-71 (Fed. Cir. 1998).  The brief cites a "circular overemphasis" on materiality that permits inequitable conduct to be found "largely on evidence of materiality with just a threshold showing of deceptive invent what may itself by largely inferred from the materiality of the alleged misconduct," citing Praxair quoting Critikon, Inc. v. Becton Dickinson Vascular Access, Inc., 120 F.3d 1253, 1257 (Fed. Cir. 1997).

    In addition to distortions in patent litigation ("relentless discovery," and disputes over privilege and crime-fraud exceptions thereof that "tax the trial court's resources and unnecessarily multipl[ies] the contentiousness of the proceedings") and prosecution ("over-disclosure to avoid any alleged omission and under-representation to avoid any alleged misrepresentation," emphasis in original), the brief raises the point, originally expressed by Judge Nichols in Burlington Indus. v. Dayco Corp., 849 F.2d 1418, 1422 (Fed. Cir. 1988):

    [Lawyers asserting inequitable conduct] get anywhere with the accusation in but a small percentage of the cases, but such charges are not inconsequential on that account.  They destroy the respect for one another's integrity, for being fellow members of an honorable profession, that previously made the bar a valuable help to the courts in making a sound disposition of their cases, and to sustain the good name of the bar itself.

    The brief argues that its proposed inequitable conduct standard, based on principles from common-law fraud ("reliance, injury and intent") would return the doctrine to its historical roots, specifically the triad of Supreme Court cases from which it arose (Keystone Driller Co. v. General Excavator Co., 290 U.S. 240 (1933); Hazel-Atlas Glass Co. v. Hartford-Empire Co., 322 U.S. 238, 250-51 (1944); and Precision Instrument Mfg. Co. v. Auto. Maint. Mach. Co., 324 U.S. 806, 814 (1945)).  These cases all involved actual fraud, wherein perjured testimony was presented, material information concealed, and specific intent to deceive established.  Importantly, the brief argues that these cases all involved detrimental reliance by the PTO on the misconduct to grant invalid patents.  The brief cites other, earlier Supreme Court cases, including Corona Cord Tire Co. v. Dovan Chem. Corp., 276 U.S. 358 (1928), where the Court refused to find the patent unenforceable even though misconduct was discerned, because the conduct "though perhaps reckless, [was] not . . . essential material to [the patent's] issue."  In contrast, the brief points out that the Federal Circuit has acknowledged that under its husbandry "the concept of inequitable conduct doctrine has expanded over time such that it no longer includes the principles of fraudulent intent and detrimental reliance as absolute requirements," citing Agfa Corp. v. Creo Prods. Inc., 451 F.3d 1366, 1375 n 3 (Fed. Cir. 2006).

    The consequence of this departure from Supreme Court principles by the Federal Circuit, according to the brief, is "an overbroad and vaguely-defined inequitable conduct defense."  Under the ABA's proposal, the first two elements (a misrepresentation or omission and PTO action in granting a patent that would not have been granted absent the misrepresentation or omission) track the principles of detrimental reliance in common-law fraud.  This amounts to an "objective but for" test for materiality (which the brief contends it is "similar to"), assuring that "inequitable conduct will only be found where the PTO's reliance . . . has resulted in actual harm through the issuance of an otherwise invalid claim."  Beneficial consequences of adopting this standard would be to "eliminate assertion of inequitable conduct 'where the patentee only committed minor missteps,'" and would "reduce the burden on the PTO by removing the incentive to over-disclose information to the examiner."  The brief envisions standards of inequitable conduct that would be distinct between the Office and during litigation, wherein misconduct that would not be sufficient to support a finding of inequitable conduct during litigation could be sufficient to deserve sanctions before the PTO.  (The brief contends that the Office has sufficient sanctions in place, such as disciplinary proceedings against practitioners, to police any such misconduct.)

    The third requirement of the ABA's proposed test for inequitable conduct, deceptive intent, would require an independent determination of specific intent to deceive, consistent with the common law fraud standard.  The brief argues that this requirement would require "independent and clear" evidence (direct or circumstantial) of specific intent that could not be substituted by "greater" showings of materiality.  The brief also argues that this requirement would be a "stronger gatekeeper" by specifically precluding assertion of the defense under Rule 11 when there is insufficient evidence to support it.

    The brief concludes that the proposed standard is "a fair and balanced approach" to solving the problems that have arisen with current inequitable conduct doctrine:

    [I]t preserves the defense as a deterrent and remedy for those relatively rare instances where it is proven that the applicant acted with fraudulent intent and the PTO detrimentally relied on such to issue otherwise invalid claims.  But it erects the defined boundaries missing from the current law, which has resulted in excess not only on litigation, but on the overall patent system.

    For additional information regarding this topic, please see:

    • "Therasense, Inc. v. Becton, Dickinson & Co. — Briefing Schedule Update," August 8, 2010
    • "BIO Files Amicus Brief in Therasense Case," August 8, 2010
    • "Pharma and Software Companies File Joint Amicus Brief in Therasense Case," August 3, 2010
    • "IPO Files Amicus Brief in Therasense Case," August 2, 2010
    • "Abbott Files Brief in Therasense Case," July 28, 2010
    • "CAFC Sets Date for Oral Argument En Banc in Inequitable Conduct Appeal," June 9, 2010
    • "Therasense, Inc. v. Becton, Dickinson & Co. — Briefing Schedule Update," May 16, 2010
    • "Therasense, Inc. v. Becton, Dickinson & Co. Briefing," May 13, 2010
    • "Federal Circuit Grants En Banc Review in Therasense v. Becton Dickinson," April 28, 2010

  • By Juan Serrano —

    Mexican Flag Following up on the note for future regulations to approve biotechnological drugs in Mexico (see "Mexico to Issue Regulations for Approval of 'Biocomparable' Drugs"), documents with comments have been uploaded to the official website of the Federal Commission for Regulatory Improvement (COFEMER).

    COFEPRIS The first of these documents is an official communication from COFEMER to COFEPRIS (the authority which oversees approvals) referring to the regulatory impact that the provisions will have, which was made public on August 9, 2010.  COFEMER is requesting, amongst other things, the following:

    – A justification for the elimination of the 3-year period in the Roche-Bolar-like research exemption in order to verify compliance of provisions in the Industrial Property Law.

    – Justification for each requirement to approve biocomparable drugs.

    – Additional information on cost impacts that the new regulations will have on industry participants.

    – Additional information on reductions of public health expenditures derived from the regulations.

    This communication has been delivered by COFEPRIS which will have to make the necessary justifications and adjustments to its proposal, before submitting anew to COFEMER.  There is no specific deadline contemplated for this purpose.  After the project is revised, if modifications are made, a new 30-day period will be granted to the general public to provide comments.

    AMELAF The second document contains a review by the Mexican Association of Pharmaceutical Laboratories (AMELAF) with a proposal for modifications to the project of regulations.  In this proposal, the main items are the following:

    – Concerning the Roche-Bolar-like exemption, AMELAF is proposing to change the wording in order for linkage review by COFEPRIS to be made only in regards to the first "molecule" (active ingredient) patent, which would be applicable both to biotech and chemical drugs.  This goes directly against the decision by the Mexican Supreme Court, which interpreted linkage regulations to include patents covering pharmaceutical formulations as well (see "Mexican Supreme Court Decides on Broad Interpretation of Linkage Regulations").  This specific proposal is very likely to be contended by AMIIF, and/or individual patent holders.

    – AMELAF is also proposing to make most regulatory requirements for the approval of a biocomparable drug subject to the discretion of the Ministry of Health on a case by case basis.  The current project contains mandatory pre-clinical and clinical trials, pharmacodinamics studies, immunity response studies in animals and in vivo studies.  The proposal by AMELAF is to make all of these requirements applicable "if necessary."

    Whereas this proposal could have some merit in order to avoid studies that would prove to be unnecessary for specific drugs, it should be allowed only if a correlating provision providing for regulatory exclusivity is passed, in order to maintain a balance between the innovators making the initial studies and subsequent market entrants.  No such provision is contained in the project.

    – Additionally, AMELAF is proposing that the term for COFEPRIS to approve a biotech drug be reduced from 235 to 180 working days, and that, if that term expires without a response, then the application is understood as granted.  This last item is not likely to be approved, as it could result in the authorization of drugs without full review of the applications by the corresponding authority, which might generate sanitary risks.

    A copy of the two documents mentioned in this article can be found here.

    Juan Serrano is an attorney with Olivares & Cia in Mexico City and frequent contributor to Patent Docs.  He can be contacted at jls@olivares.com.mx.

  • By James DeGiulio —

    Genzyme Genzyme's manufacturing problems with their $300,000 per year drug Fabrazyme have prompted patients who depend on the enzyme replacement drug to ask that Health and Human Services (HHS) Secretary Kathleen Sebelius exercise the government's "march-in rights" under the Bayh-Dole Act.  The 1980 law empowers the federal agency funding the research, here the HHS, to abrogate Genzyme's U.S. Patent Nos. 5,356,804 and 5,560,757 on the drug, allowing other companies to fill the demand.  The agency is empowered to provide licenses to other interested parties when the "health or safety needs" of the American people are not being "reasonably satisfied" by the patent holder or its exclusive licensee.

    Shire Pharmaceuticals Despite numerous petitions, no agency has ever exercised its "march-in" powers, and the NIH has repeatedly denied formal requests to march in, as they did with regard to CellPro and Norvir.  However, this is the first time actual patients have alleged that a patent-holder isn't satisfying their needs.  Unfortunately, even if the petition is granted, it is unclear which company would be equipped to take immediate advantage of an opportunity to produce Fabrazyme.  One possibility could be UK-based Shire, who earlier this year applied to the FDA for market approval of Replegal, an enzyme-replacement drug similar to Fabrazyme.  Shire had previously offered to supply Replegal drug free of charge to U.S. patients taking Fabrazyme, but this summer Shire announced it could no longer provide Replegal to new patients.

    Fabrazyme The petition was filed by a family prone to Fabry disease, a rare genetic disorder that interferes with fat metabolism.  Patients with Fabry disease build up fats in body tissues, leading to kidney and heart failure, and usually death.  The disease is also known to produce severe pain in the arms and legs, severe intestinal problems, profound fatigue and other maladies.  About 1,500 patients with Fabry disease depend on Fabrazyme, which was approved in 2001.

    Due to Genzyme's manufacturing issues, only 30 percent of the needed amount of Fabrazyme is available.  Earlier this year, Genzyme discovered viral contamination in equipment used to produce Fabrazyme, and later discovered foreign particles in several lots of drug vials.  As a result, the company has been fined $175 million by the FDA.

    James DeGiulio has a doctorate in molecular biology and genetics from Northwestern University and is a graduate of Northwestern University School of Law.  Dr. DeGiulio is a member of MBHB's 2010 associate class and he can be contacted at degiulio@mbhb.com.